Home/Filings/4/0001104659-10-055361
4//SEC Filing

Holmes David A 4

Accession 0001104659-10-055361

CIK 0000744962other

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 6:03 AM ET

Size

15.8 KB

Accession

0001104659-10-055361

Insider Transaction Report

Form 4
Period: 2010-08-13
Transactions
  • Purchase

    Common Stock

    2010-11-02$0.01/sh+3,725,719$55,88618,725,719 total(indirect: By Pharmachem Laboratories, Inc.)
  • Purchase

    Convertible Preferred Shares Series J 8%

    2010-11-02$281.37/sh+3,000$844,11021,193,230 total(indirect: By Pharmachem Laboratories, Inc.)
    Exercise: $1.22Common Stock (2,467,511 underlying)
  • Purchase

    Warrants

    2010-11-02+1,134,96622,328,196 total(indirect: By Pharmachem Laboratories, Inc)
    Exercise: $1.22From: 2008-03-11Exp: 2013-03-11Common Stock (1,134,966 underlying)
  • Purchase

    Warrants

    2010-11-02+777,77823,105,974 total(indirect: By Pharmachem Laboratories, Inc)
    Exercise: $2.20From: 2008-03-11Exp: 2013-03-11Common Stock (777,778 underlying)
Footnotes (8)
  • [F1]The securities reported herein (the "Securities") are owned by Pharmachem Laboratories, Inc.
  • [F2]The Securities may be deemed to be indirectly beneficially owned by David A. Holmes under Rule 16a-1(a)(2)(iii), since David Holmes is the controlling shareholder of Pharmachem Laboratories, Inc.
  • [F3]Anytime after September 10, 2007.
  • [F4]According to the Certificate of Amendment of the Certificate of Designation of the Company which creates the Series J 8% Convertible Preferred Stock and was filed with the Securities Exchange Commission on September 12, 2007, the preferred shares are convertible at any time at the option of the holder. Additionally, on the fourth anniversary of the issue date, the Company shall redeem the then outstanding Preferred Stock.
  • [F5]This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, and (iii) 2,467,511 shares of Common Stock which may be issued by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended.
  • [F6]This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, (iii) 2,467,511 shares of Common Stock which may be issuable by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended (the "Act"), and (iv) 1,134,966 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act.
  • [F7]This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, (iii) 2,467,511 shares of Common Stock which may be issuable by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended (the "Act"), (iv) 1,134,966 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act, and (v) 777,778 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act.
  • [F8]No price was given to the warrants as they were attached to the Convertible Preferred Shares Series J 8%.

Documents

1 file

Issuer

NUTRITION 21 INC

CIK 0000744962

Entity typeother

Related Parties

1
  • filerCIK 0001498510

Filing Metadata

Form type
4
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 6:03 AM ET
Size
15.8 KB